Zacks Upgrades Apricus Biosciences to “Neutral” (APRI)
Apricus Biosciences (NASDAQ:APRI) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued on Thursday. The firm currently has a $2.00 price objective on the stock. Zacks‘s price objective would indicate a potential upside of 3.63% from the company’s current price.
Apricus Biosciences (NASDAQ:APRI) traded up 0.52% during mid-day trading on Thursday, hitting $1.94. The stock had a trading volume of 15,901 shares. Apricus Biosciences has a 52-week low of $1.66 and a 52-week high of $2.71. The stock’s 50-day moving average is $2.01 and its 200-day moving average is $2.22. The company’s market cap is $73.9 million.
Apricus Biosciences (NASDAQ:APRI) last released its earnings data on Tuesday, August 12th. The company reported $0.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.04) by $0.09. The company had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.45 million. Analysts expect that Apricus Biosciences will post $-0.29 EPS for the current fiscal year.
Separately, analysts at Cantor Fitzgerald upgraded shares of Apricus Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, May 27th. They now have a $3.00 price target on the stock, up previously from $2.50.
Apricus Biosciences, Inc, formerly NexMed, Inc, is a pharmaceutical research and development company focused on the design and development of products and technologies in multiple therapeutic areas, including oncology, sexual dysfunction, autoimmune diseases and pain/inflammation.
To view Zacks’ full report, visit Zacks’ official website.